145 related articles for article (PubMed ID: 27608327)
1. Dendrimers as Innovative Radiopharmaceuticals in Cancer Radionanotherapy.
Liko F; Hindré F; Fernandez-Megia E
Biomacromolecules; 2016 Oct; 17(10):3103-3114. PubMed ID: 27608327
[TBL] [Abstract][Full Text] [Related]
2. Design of multivalent galactosyl carborane as a targeting specific agent for potential application to boron neutron capture therapy.
Lai CH; Lin YC; Chou FI; Liang CF; Lin EW; Chuang YJ; Lin CC
Chem Commun (Camb); 2012 Jan; 48(4):612-4. PubMed ID: 22114760
[TBL] [Abstract][Full Text] [Related]
3. Boron neutron capture therapy: Moving toward targeted cancer therapy.
Mirzaei HR; Sahebkar A; Salehi R; Nahand JS; Karimi E; Jaafari MR; Mirzaei H
J Cancer Res Ther; 2016; 12(2):520-5. PubMed ID: 27461603
[TBL] [Abstract][Full Text] [Related]
4. Boron containing magnetic nanoparticles for neutron capture therapy--an innovative approach for specifically targeting tumors.
Tietze R; Unterweger H; Dürr S; Lyer S; Canella L; Kudejova P; Wagner FM; Petry W; Taccardi N; Alexiou C
Appl Radiat Isot; 2015 Dec; 106():151-5. PubMed ID: 26242559
[TBL] [Abstract][Full Text] [Related]
5. Dodecaborate lipid liposomes as new vehicles for boron delivery system of neutron capture therapy.
Ueno M; Ban HS; Nakai K; Inomata R; Kaneda Y; Matsumura A; Nakamura H
Bioorg Med Chem; 2010 May; 18(9):3059-65. PubMed ID: 20371186
[TBL] [Abstract][Full Text] [Related]
6. Dendrimers and dendritic polymers in drug delivery.
Gillies ER; Fréchet JM
Drug Discov Today; 2005 Jan; 10(1):35-43. PubMed ID: 15676297
[TBL] [Abstract][Full Text] [Related]
7. Boron neutron capture therapy of cancer: current status and future prospects.
Barth RF; Coderre JA; Vicente MG; Blue TE
Clin Cancer Res; 2005 Jun; 11(11):3987-4002. PubMed ID: 15930333
[TBL] [Abstract][Full Text] [Related]
8. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
Maruyama K; Ishida O; Kasaoka S; Takizawa T; Utoguchi N; Shinohara A; Chiba M; Kobayashi H; Eriguchi M; Yanagie H
J Control Release; 2004 Aug; 98(2):195-207. PubMed ID: 15262412
[TBL] [Abstract][Full Text] [Related]
9. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
[TBL] [Abstract][Full Text] [Related]
10. Insight into the mechanisms underlying tumor response to boron neutron capture therapy in the hamster cheek pouch oral cancer model.
Aromando RF; Heber EM; Trivillin VA; Nigg DW; Schwint AE; Itoiz ME
J Oral Pathol Med; 2009 May; 38(5):448-54. PubMed ID: 19141057
[TBL] [Abstract][Full Text] [Related]
11. Advances in anticancer radiopharmaceuticals.
Jackson MR; Falzone N; Vallis KA
Clin Oncol (R Coll Radiol); 2013 Oct; 25(10):604-9. PubMed ID: 23870756
[TBL] [Abstract][Full Text] [Related]
12. [Development of BNCT based on research using accelerator based neutron source].
Kumada H
Igaku Butsuri; 2012; 32(3):104-10. PubMed ID: 24592679
[No Abstract] [Full Text] [Related]
13. Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy.
Luderer MJ; de la Puente P; Azab AK
Pharm Res; 2015 Sep; 32(9):2824-36. PubMed ID: 26033767
[TBL] [Abstract][Full Text] [Related]
14. Dendrimers in oncology: an expanding horizon.
Tekade RK; Kumar PV; Jain NK
Chem Rev; 2009 Jan; 109(1):49-87. PubMed ID: 19099452
[No Abstract] [Full Text] [Related]
15. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy.
Shukla S; Wu G; Chatterjee M; Yang W; Sekido M; Diop LA; Müller R; Sudimack JJ; Lee RJ; Barth RF; Tjarks W
Bioconjug Chem; 2003; 14(1):158-67. PubMed ID: 12526705
[TBL] [Abstract][Full Text] [Related]
16. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy.
Ting G; Chang CH; Wang HE
Anticancer Res; 2009 Oct; 29(10):4107-18. PubMed ID: 19846958
[TBL] [Abstract][Full Text] [Related]
17. [Current Status and Prospects on PET Radiopharmaceuticals for Radiotherapy].
Yoshimoto M
Igaku Butsuri; 2015; 35(1):10-5. PubMed ID: 26753391
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of boron compounds to tumor with polyethylene-glycol binding liposome by using neutron capture autoradiography.
Yanagië H; Ogura K; Takagi K; Maruyama K; Matsumoto T; Sakurai Y; Skvarc J; Illic R; Kuhne G; Hisa T; Yoshizaki I; Kono K; Furuya Y; Sugiyama H; Kobayashi H; Ono K; Nakagawa K; Eriguchi M
Appl Radiat Isot; 2004 Oct; 61(4):639-46. PubMed ID: 15246411
[TBL] [Abstract][Full Text] [Related]
19. Boron analysis and boron imaging in biological materials for Boron Neutron Capture Therapy (BNCT).
Wittig A; Michel J; Moss RL; Stecher-Rasmussen F; Arlinghaus HF; Bendel P; Mauri PL; Altieri S; Hilger R; Salvadori PA; Menichetti L; Zamenhof R; Sauerwein WA
Crit Rev Oncol Hematol; 2008 Oct; 68(1):66-90. PubMed ID: 18439836
[TBL] [Abstract][Full Text] [Related]
20. Use of boron cluster-containing redox nanoparticles with ROS scavenging ability in boron neutron capture therapy to achieve high therapeutic efficiency and low adverse effects.
Gao Z; Horiguchi Y; Nakai K; Matsumura A; Suzuki M; Ono K; Nagasaki Y
Biomaterials; 2016 Oct; 104():201-12. PubMed ID: 27467416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
